Nov 12, 2025 4:01pm EST iBio Reports Q1 Fiscal Year 2026 Financial Results and Provides Corporate Update
Oct 30, 2025 7:00am EDT iBio Unveils New Non-Human Primate Data on IBIO-610, an Activin E Antibody with Strong Therapeutic Potential for Fat-Selective Weight-Loss and Weight Maintenance
Oct 23, 2025 7:00am EDT iBio to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference
Oct 21, 2025 7:00am EDT iBio to Present New Preclinical Data on Its Activin E Antibody at Two Upcoming Scientific Conferences, ObesityWeek® and PEGS Europe 2025
Sep 05, 2025 7:30am EDT iBio Reports Fiscal Year 2025 Financial Results and Provides Corporate Update
Jun 24, 2025 7:00am EDT iBio and AstralBio Unveil Obesity Program with Novel Amylin Agonist Antibody Demonstrating Promising In Vivo Results
